Abstract -Nitric oxide (NO), synthesized from L-arginine by three isoforms of NO synthase (NOS), is a gaseous signaling molecule with an astonishingly wide range of biological and pathophysiological activities, including vasorelaxation, angiogenesis, anti-inflammation, and anti-apoptosis in mammalian cells. Recent studies have shown that NO donors and inhaled NO convert to biologically active NO under biological conditions and act as a signaling molecule in pathophysiological conditions. This review will discuss the roles of NO and its potential therapeutic implication in various human diseases, such as tumor, vascular regeneration, hypertension, wound healing, and ischemia-reperfusion injury.
INTRODUCTION
NO, first characterized as a major endothelial-derived relaxing factor (Furchgott and Zawadzki, 1980) , is a gaseous molecule with a wide range of physiological and pathological activities (Ignarro et al., 1987) , including smooth muscle relaxation, inhibition of platelet aggregation, and neurotransmission. NO, synthesized from L-arginine by the reaction of three NOS isozymes, such as eNOS expressed in endothelial cells, iNOS induced in immune cells including macrophages, and nNOS expressed in neuronal cells, has received intense media coverage due to its role as a biological messenger and was named 'molecule of the year' in 1992 by the journal Science. Moreover, this molecule has been investigated for it's critical role in vascular physiology, immune response to bacterial infections, and neurotransmission. In 1998, Drs. Furchgott, Ingnarro and Murad shared the Noble Prize in Physiology and Medicine for 'the first discovery that a gas can act as a signal molecule', emphasizing that NO produced by mammalian cells is an important signaling mediator in various biological systems such as immunology, physiology, and neuroscience.
Various biological activities of NO are highly associated with chemical reactivity for intracellular target molecules, such as transition metal, free thiol (sulfhydryl) group, tyrosine residues, superoxide anion, and molecular oxygen. The earliest described intracellular receptors for NO are heme and non-heme iron-containing proteins, including hemoglobin, soluble guanylyl cyclase (sGC), and aconitase. In particular, binding of NO to the heme group of sGC promotes its catalytic activity, increasing the conversion of GTP to cGMP, which in turn activates protein kinase G (Murad, 1986) . The NO-cGMP pathway plays an important role in NO-mediated physiological events, such as vasodilation and penile erection. Despite identification of sGC as the first receptor against NO for eliciting cellular function, it has become clearly demonstrated that NO can exert most of its cellular influence in a cGMP-independent manner. NO interacts with sulfhydryl groups of proteins and nonprotein biomolecules to generate S-nitrosothiol, designated S-nitrosylation. S-nitrosylation exhibits a wide rage of cellular effects of NO on pathophysiological processes in the cardiovascular system and vascular disorders (Lima et al., 2010) . In addition, S-nitrosylation on catalytic thiols of caspase family proteases prevents cells from apoptotic cell death (Kim et al., 1997b; Li et al., 1997) . Reaction of NO with superoxide anion generates the strong oxidant peroxynitrite, leading to cytotoxicity or apoptotic cell death. However, NO reaction with molecular oxygen decreases its biological effect in pathophysiological conditions as a result of reduced bioavailability via the production of the stable and inert oxidation products, nitrite and nitrate. Taken together, NO plays versatile functions in various pathophysiological conditions via reactions with different intracellular receptors and target molecules. Here, we review the biological roles and pathophysiological mechanisms of action of NO and discuss the therapeutic potential of NO in various human diseases.
NO AND NITRIC OXIDE SYNTHESES
NO is a small, odorless, colorless, endogenous, and free radical molecule, which highly diffuses in water and through cellular membranes. However, its high reactivity limits its short half-life in biological systems. Interestingly, NO elicits different reactions in cells in a concentration-dependent manner. At low concentrations, it is a potent biological messenger in a variety of tissues, with a wide range of physiological functions such as vasodilation, inhibition of platelet aggregation, regulation of neurotransmission and natural defense of the immune system. Conversely, high concentrations of NO are involved in the immune system during cytotoxicity of tumor cells, infection of microorganisms, and inflammation (Nathan, 1997) .
NO is endogenously produced by a group of homodimeric NOS enzymes through enzymatic oxidation of the guanidine group of L-arginine in the presence of oxygen (Ignarro et al., 1987; Nathan, 1992) . It is hydroxylated to generate L-hydroxyarginine, which is further oxidized, yielding L-citrulline and NO (Marletta et al., 1998) (Fig. 1) . All three NOS isozymes possess reductase and highly conserved oxygenase polypeptide domains within each monomer; thus, this enzyme catalyzes two sequential NADPH-and O 2 -dependent mono-oxygenase reactions to produce NO from L-arginine. These isoforms are denoted by descriptive terms, based on the requirement of intracellular calcium oscillation for full activity as well as gene expression (Table I) . Two NOS isoforms, eNOS and nNOS, are constitutively expressed and operate their catalytic activities in a calcium-dependent manner, consequently producing NO at low concentrations (nM -pM) (Forstermann et al., 1995; Gath et al., 1996) . These constitutive NOS isoforms require a transient increase in intracellular calcium levels and several cofactors for their enzymatic activity, which promotes the release of NO over the course of several minutes. Specifically, these NOS isoforms increase their enzymatic activity at a specific level of intracellular calcium, but inactivate at a low level of calcium. These constitutive isoforms are key modulators in physiological processes such as memory, long-term potentiation, and depression in the nervous system and regulate blood pressure (vasorelaxation) in the vascular system.
The comparatively small quantities of NO produced by constitutive NOS isoforms is important for cellular signaling events such as blood pressure regulation and neurotransmission. The other isoform iNOS is induced in response to cytokines and/or bacterial products such as interferon-γ, interleukins, TNF-α, and lipopolysaccharides (LPS) in various cell types including macrophages, hepatocytes, dendritic cells, fibroblasts, chondrocytes, osteoclasts, astrocytes, and epithelial cells, which results in the production of large amounts of NO for several days Jun et al., 1994) . The catalytic activity of iNOS is independent of intracellular calcium level, but is required for cofactors. Although the low level of NO produced by constitutive NOS isoforms has been known to play an important physiological role in neuronal and vascular systems, the larger amounts of NO generated by iNOS functions both as a regulator and effecter during infection and inflammation. One effecter function includes direct cytotoxicity toward tumor cells, microorganisms, and host cells. The cytotoxicity capacity of NO has been associated with S-nitrosylation, nitrosyl-iron complex formation, gene expression, and DNA mutation, which have been confirmed in numerous subcellular systems using diverse cell targets, such as cytosol, mitochondria, and nuclei (Kroncke et al., 1997) . In addition, there are some other spliced variants or isoforms of NOS, such as mitochondrial NOS (mtNOS) and NOS in skeletal muscle. mtNOS is an α-isoform of nNOS that is localized at the inner mitochondria membrane in rat liver mitochondria (Tatoyan and Giulivi, 1998; Elfering et al., 2002) , and NOS in skeletal muscle is a μ-isoform of nNOS which is localized beneath the sarcolemma of fast twitch muscle fibers (Silvagno et al., 1996) . The NOS isoforms are phosphorylated by various kinases such as cyclic AMP-dependents protein kinase, cyclic GMP-dependents protein kinase, protein kinase C, or Ca 2＋ /calmodulin-dependent protein kinase (Nathan and Xie, 1994; Sase and Michel, 1997; Fleming et al., 2001) . Phosphorylation of NOS by these kinases regulates an increase or decrease in its catalytic activity. For example, the phosphatidylinositol-3-OH-kinase (PI3K)/Akt pathway has been shown to directly activate eNOS by phosphorylation at serine-1177, which is induced by various cytokines and mechanical forces such as shear stress (Dimmeler et al., 1999) . Furthermore, eNOS is co-and post-translational modified by myristoylation, palmitoylation or acylation, which targets it to the cytoplasmic membrane or other intracellular organelles from the cytosol (Sase and Michel, 1997) . Therefore, the enzymatic activity of NOS can be regulated by various post-translational modifications.
PATHOPHYSIOLOGICAL ACTION MECHANISMS OF NO
NO is a small, hydrophobic molecule that can easily pass through membranes and possesses autocrine and/or paracrine functions. In addition, NO is a diffusible, multifunctional, transcellular messenger that has been implicated in numerous physiological and pathological conditions. The biological activity of NO is dependent on complex formation with iron, thiol groups of cysteine, and tyrosine residues in proteins or enzymes. In many cells, NO reacts with the cofactor heme-iron in sGC, which results in conformational changes that triggers its enzymatic activity to produce cGMP from GTP. The cGMP engages various downstream targets including protein kinases, phosphodiesterases, and ion channels, resulting in modulation of cell functions such as smooth muscle relaxation, platelet aggregation, and synaptic plasticity. These cellular events are associated with the activation of cGMP-dependent kinase and involves various physiological functions, such as regulation of vascular tone and neurotransmission. However, some studies have reported that regulation of cell function by NO can be associated with a diverse cGMP-independent pathway (Schmidt et al., 1993; Chung et al., 2001) . Low concentrations of NO by nNOS and eNOS are mainly involved in the cGMP-dependent pathway, but high concentrations of NO by iNOS are implicated in physiological and biological functions through either cGMP-dependent or independent pathways (Kim et al., 1997b; Chung et al., 2001) . Indeed, NO can inhibit apoptosis via inhibition of caspase activity through the activation of cGMP-dependent protein kinase and redox-based S-nitrosylation of cysteine residues in the catalytic site of caspase (Kim et al., 1997a; Li et al., 1997; Dash et al., 2003) . We have previously reported that high doses of NO may inhibit apoptosis through both cGMP-dependent and independent mechanisms (Kim et al., 1997b; Kim et al., 1999) . cGMP can also activate myosin light chain phosphatase (Surks, 2007) , Ca 2＋ channels (Spedding et al., 1986 ), PI3K-dependent Akt (Ha et al., 2003) , and ATP-sensitive K ＋ channels (Archer et al., 1994) , as well as regulate smooth muscle cell growth (Garg and Hassid, 1989) and gene expression (Kroncke, 2003) . NO can modify proteins through direct chemical reactions, without the requirement of enzymatic activity. NO directly interacts with a sulfhydryl group and iron of various intracellular molecules and proteins, leading to conformation changes. This modification is a well-known cGMPindependent pathway of NO and requires larger amounts of NO than mechanisms involving activation of sGC. The interaction of NO with a sulfhydryl group results in the production of a RS-NO form via the direct attachment of NO to the thiol group of cysteine residues in various proteins including albumin, hemoglobin, Ras, and caspase family proteins. In addition, many ion channels, such as ryanodine receptors, NMDA receptor, and L-type Ca 2＋ channels, which are S-nitrosylated are nearly as broad as mechanisms controlled by cGMP (Ahern et al., 2002) . S-nitrosylation is emerging as an important post-translational modification of ion channels, which provides a route by which NO can regulate electrical activity without stimulating production of cGMP. Biological functions of S-nitrosylation are associated with the regulation of apoptosis via caspases, gene expression by NF-κB, HIF-1α or IRE, and blood flow by hemoglobin (Foster et al., 2009 ). In addition, formation of a nitrosyl-iron complex is an important cellular event for inhibiting the catalytic activity of several enzymes, such as aconitase, ferrochelatase, and cytochrome c oxidase (Kim et al., 1995b; Taylor and Moncada, 2010) , resulting in an increase in cytotoxicity and mitochondrial dysfunction. These observations indicate that NO-mediated cGMP production is associated with its beneficial role in physiological and pathological conditions and that cGMP-independent cellular action is linked to consequences of either cytotoxicity or cytoprotection in a pathophysiological condition.
NO THERAPY FOR HUMAN DISEASES
NO is an autocrine and paracrine signaling molecule whose half-life and diffusion gradient are limited by scavenging reactions with hemoglobin, myoglobin, small ironsulfur complexes, molecular oxygen, and radicals. Interestingly, nitrite, a primary one-electron oxidation product of NO by reaction with macular oxygen, can act as a selective NO donor because of reduction back to NO by several mechanisms, including, but not limited to, deoxyhemoglobin, deoxymyoglobin, xanthine oxidoreductase, acidic disproportionation, and mitochondrial complex IV Dezfulian et al., 2007) . Therefore, NO donors, nitrite, and inhaled NO can be considered as endocrine molecules that are transported in the blood, accumulate in tissue, and have the potential to be converted back to NO under physiological and pathologic conditions, resulting in an increase in cGMP production, protein modification by S-nitrosylation, and cellular signaling events (Cosby et al., 2003; Kumar et al., 2008) . Based on these reasons, inhaled NO and administrated NO donors and nitrite are used as therapeutic drugs for several human diseases.
Effect of NO on tumor therapy
The first report that NO can suppress or arrest tumor growth was initially suggested by several studies which demonstrated that immune-activated murine macrophages synthesize nitrite and nitrate leading to cytotoxicity against tumor cells and bacteria (Stuehr and Marletta, 1985; Hibbs et al., 1987; Hibbs et al., 1988) . Macrophages infiltration into tumors synthesize NO, which attributes to the formation of iron-nitrosyl complex, as determined by EPR spectroscopy, which is responsible for cytostatic and cytotoxic effects on tumor cells, including inhibition of mitochondrial respiration and DNA replication (Granger et al., 1980; Yim et al., 1993) . This cytotoxic effect during in vivo tumor progression was inhibited by continuous infusions of the NOS inhibitor N-monomethyl-L-arginine into tumor-bearing mice. However, a study by Moncada demonstrated that two human colorectal adenocarcinoma primary cell lines, SW-480 and SW620, express Ca 2＋ -independent NOS and produce NO (Radomski et al., 1991) . Tumor-derived NO inversely correlates with their metastatic potential. Additionally, when injected with tumor cells, tumor growth and metastasis was greater in iNOSdeficient mice than in wild-type mice (Wei et al., 2003) , indicating that the physiological expression of iNOS in host cells directly inhibits tumor growth and metastasis. These evidences support the initial hypothesis for the cytotoxic and cytostatic effects of NO production on tumor progression.
The anti-tumor mechanism of NO is directly associated with the stimulation of tumor cell apoptosis by the tumor suppressor p53 up-regulation and caspase activation (Forrester et al., 1996; Messmer and Brune, 1996) as well as inhibition of tumorigenesis and tumor growth by cell cycle arrest and necrotic cell death (Shimaoka et al., 1995; Lala and Chakraborty, 2001; Trikha et al., 2001; Le et al., 2005) . Exogenous and endogenous NO production has been shown to increase p53 protein accumulation, and overexpression of p53 in a variety of human tumor cell lines results in down-regulation of iNOS expression through inhibition of its promoter activity (Forrester et al., 1996) . This observation reveals that there is a negative feedback loop mechanism between iNOS expression and p53 accumulation in which p53 safeguards against DNA damage through p53-mediated suppression of iNOS gene overexpression, reducing the potential for NO-induced DNA damage and mutation. In addition, NO initiates apoptosis or necrotic cell death by alterations in the expression of pro-and anti-apoptotic Bcl-2 family members, cytochrome c relocation, activation of caspase family proteases, mitochondrial dysfunction, chromatin condensation, and DNA fragmentation (Brune et al., 1998) . These evidences indicate that NO generated in the intratumoral microenvironment may prove to be a useful tumor therapy by promoting direct cellular toxicity (apoptotic and necrotic cell death) and cytostatic effects (cell cycle arrest).
Conversely, NO may be acting as part of a signaling cascade for tumor neovascularization in vivo, leading to the promotion of tumor metastasis, whereas in vitro cytotoxic properties contribute to the apparent slowing of tumor growth. Therefore, NO function in tumors still remains controversial with evidence suggesting its contribution to both pro-and anti-tumor effects. This contradiction has been suggested to be dependent on the concentration of NO, with high concentrations responsible for anti-tumor activity through the promotion of cytotoxicity and lower NO concentrations which lead to the promotion of tumor growth and metastasis by tumor angiogenesis (Chinje and Stratford, 1997) . Although the concentrations of NO at which this switch occurs are still not clear, the opposite effects of NO on tumor cells can depend on cell type or the concentration of certain cellular components, such as iron or thiols (Kim et al., 2000) .
The mechanism by which NO acts as a molecule possessing pro-tumor activity can be associated with the inhibition of tumor cell apoptosis by inhibition of the seven members of the caspase family via S-nitrosylation (Kim et al., 1997a; Li et al., 1997) , inhibition of the Apaf-1/caspase-9 apoptosome (Zech et al., 2003) , accumulation and nitration of p53 (Forrester et al., 1996; Chazotte-Aubert et al., 2000) and the induction of heme oxygenase-1 and heatshock protein 70 (Kim et al., 1995a; Kim et al., 1995b) . In addition, several studies have shown promotion of tumorigenesis by NO in an in vivo model. For examples, iNOSdeficient mice decreased adenoma development (Ahn and Ohshima, 2001 ), B16-F1 melanoma growth (Konopka et al., 2001 ) and mouse lung tumorigenesis (Kisley et al., 2002) , probably by negative regulation of vascular endothelial growth factor (VEGF) expression. Furthermore, NO can directly interact with DNA molecules, resulting in G:C →A:T transitions and DNA strand breakage by causing N-nitrosylation of deoxynucleotides and yielding deaminated DNA bases (Kroncke et al., 1997) . In addition, NO reacts with intracellular superoxide anion to produce the strong oxidant peroxynitrite, which induces DNA strand breakage via N-nitrosamine formation and subsequent alkylation reaction. Indeed, NO has been shown to induce oxidative DNA damage in immune-activated macrophages (deRojas-Walker et al., 1995) and to inhibit enzymes involved in DNA repair (Kroncke et al., 1997) . These results indicate that NO can increase tumor growth via inhibition of caspase activity as well as initiate tumor promotion via promotion of nucleotide base mutations.
The dual role of NO in tumors is still a dilemma, but some investigations have shown that administration of several types of NO donors reveals the beneficial effects of NO in tumor therapy. Treatment with the non-specific NOS inhibitor, N G -monomethyl-L-arginine, exhibits increases in survival rate in MDA-MB-231 cells under hypoxic conditions (Matthews et al., 2001) , whereas NOS inhibitors selectively reduce tumor blood flow in murine adenocarcinoma and melanoma in vivo (Andrade et al., 1992) , suggesting that NO can play a dual role in tumor toxicity and tumor angiogenesis. The iNOS inducer (N-(4-Hydroxyphenyl) retinamide) and NO pro-drug (diethylamine NONOate; DEA/NO, which decomposes spontaneously in solution at physiological pH and temperature, to generate up to 2 molar equivalents of NO) have been shown to exhibit apoptosis and anti-invasive effects against breast cancer cells and their bone metastases in an animal model (Simeone et al., 2006) . In addition, JS-K, a pro-drug designed to release NO following reaction with glutathione S-transferases, induces apoptosis in human myeloma cells, which was associated with caspase protease activation, PARP cleavage, increased Fas/CD95 expression, anti-apoptotic Mcl-1 cleavage, and Bcl-2 phosphorylation, as well as the release or relocation of cytochrome c, apoptosis-inducing factor, and endonuclease G release via DNA damage and JNK activation (Kiziltepe et al., 2007) . These studies suggest that exploitation of NO concentration-dependent biological effects on tumor growth, angiogenesis, and apoptosis offers a new opportunity to improve the efficacy of anti-tumor therapy.
Effect of NO on therapeutic angiogenesis
Angiogenesis is the formation of new blood vessels from pre-existing vessels providing new routes for blood circulation and is strongly regulated in many physiological and pathological conditions (Folkman and Shing, 1992) . Angiogenesis is a fundamental step in a variety of physiological (wound healing and embryonic development) and pathological (tumor progression and metastasis, rheumatoid arthritis, psoriasis, ischemic disease, cardiac infarction) conditions. Chronic organ and tissue ischemia due to defective blood circulation is a feature of several human diseases such as myocardial infarction, cerebral ischemic injury, and limb ischemia, for which minimal therapeutic strategies exist. Angiogenesis is an important process for supplying metabolic needs such as nutrients, growth factors, and molecular oxygen to sites of tissue repair or regeneration. Improvement of the angiogenic process can repair ischemia-associated tissue damage, and thus has served as a significant tool for therapeutic angiogenesis. Therefore, angiogenic inducers including the proangiogenic factor VEGF have been used as therapeutic drugs for ischemic disease, wound healing, and tissue regeneration (Folkman and Shing, 1992) .
NO has been shown to increase neovascularization in vivo (Namkoong et al., 2008) and is a component of the pathways underlying VEGF-activated endothelial cell proliferation. However, the mechanism of action by which NO acts as an upstream or a downstream mediator of VEGF has not been clearly elucidated. VEGF promotes phosphorylation-dependent eNOS activation and the release of NO via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt cascade (Papapetropoulos et al., 1997) . The NOS inhibitor, N G -nitro-L-arginine methyl ester, blocks VEGF-induced angiogenesis in rabbit cornea (Ziche et al., 1997) . In eNOS-deficient mice, the angiogenic response to hind-limb ischemia was impaired and could not be reversed by administration of VEGF (Murohara et al., 1998) . On the other hand, there is a growing body of evidence which shows that NO up-regulates VEGF (Dulak et al., 2000; Zhang et al., 2003) . NO has been shown to both increase and decrease VEGF production via modulation of HIF-1α expression. Indeed, some authors have reported that NO mediates the suppression of hypoxia-induced production of VEGF in smooth muscle cells by decreasing HIF-1α DNA binding activity (Sogawa et al., 1998; Huang et al., 1999) , whereas others have shown enhanced HIF-1 binding activity in response to NO in human glioblastoma and rat smooth muscle cells (Dulak et al., 2000; Kimura et al., 2000) . This opposing mechanism may be due to different concentrations of NO treated in cells. Although VEGF promotes angiogenesis by eNOS-dependent NO production in vitro and in vivo (Ziche et al., 1997; Namkoong et al., 2008) , the capillary growth stimulated by bFGF does not require NO production, and its angiogenic activity was inhibited by treatment with exogenous NO donors (RayChaudhury et al., 1996; Ziche et al., 1997) . These observations indicate that VEGF and bFGF activate distinct angiogenesis signaling pathways.
Many researches for development and identification of new angiogenic inducers have recently gained a growing interest for the treatment of ischemic diseases and wound healing. NO acts both as a positive regulator of HIF-1α activation and as an upstream or a downstream mediator of VEGF, which places the small radical NO at a central position in the angiogenic process (Papapetropoulos et al., 1997; Brune and Zhou, 2007) , suggesting that NO therapy would be very beneficial for therapeutic angiogenesis. The low concentrations of NO produced by eNOS activation play a critical role in modulating angiogenesis activity, because genetic deletion of this enzyme diminishes ischemia-induced angiogenesis and pericyte recruitment (Fukumura et al., 2001; Yu et al., 2005) . Consistent with these observations, transfection with the eNOS gene has been shown to promote wound healing and cardioprotective effects including augmentation of angiogenic responses Yu et al., 2005) . Various agents that promote eNOS-dependent NO production induce therapeutic angiogenesis Schgoer et al., 2009; Chung et al., 2010) , leading to improved function and tissue integrity in mouse hindlimb ischemia, penile dysfunction, and wound healing models. A recent study demonstrates that treatment with sodium nitrite as an in vivo NO-generating compound promotes vascular angiogenesis and restores blood flow in a murine model system of hind-limb ischemia (Kumar et al., 2008) . We also demonstrated that treatment with the NO donor S-Nitroso-N-penicillamine (SNAP) increases angiogenesis in eNOSdeficient mice and blood supply in a mouse model (Namkoong et al., 2008) . Taken together, these observations indicate that elevation of NO production would be beneficial for therapeutic angiogenesis, yet there are currently no effective means to selectively deliver NO to target organs (ischemic tissues and wound sites) to promote angiogenesis.
Effect of NO on hypertension
The initial study by Furchgott and Zawadzki (1980) reported that endothelial cells were responsible for vasorelaxation by producing endothelium-derived relaxing factor, which was later identified as NO (Ignarro et al., 1987) . Numerous studies have confirmed the vasodilatory effects of NO in several animal models and humans (Cosby et al., 2003; Hunter et al., 2004; Tsuchiya et al., 2005) . Knocking out the gene encoding eNOS in mice results in significant hypertension, which is unaffected by treatment with NOS inhibitors, and endothelium-intact aortic rings removed ex vivo from these animals display no relaxation to acetylcholine (Huang et al., 1995) , indicating that non-endothelial isoforms of NOS may be involved in maintaining blood pressure. These results indicate that elevation of NO production in the vasculature can be an important therapeutic strategy for hypertension. Indeed, exogenous NO delivery is currently the first line of treatments for post-operative pulmonary hypertension or primary pulmonary hypertension of the newborn (PPHN) being managed on the intensive care unit, as it reduces pulmonary arterial pressure quickly (Beghetti et al., 1995; Steudel et al., 1999) . PPHN is a condition that is associated with a high pulmonary vascular resistance and extremely low systemic oxygenation. Delivery of sodium nitrite by aerosol in sheep models of PPHN elicited a rapid and sustained reduction (approximately 65%) in hypoxia-induced pulmonary hypertension, with a magnitude approaching that of the effects of 20 ppm NO gas inhalation (Hunter et al., 2004) . This reduction was directly associated with the immediate appearance of NO in expiratory gas. Notably, from a therapeutic standpoint, short-term delivery of nitrite dissolved in saline through nebulization sustained pulmonary vasodilation with no clinically significant increase in blood methemoglobin levels. These data support the concept that nitrite is a vasodilator acting through conversion to NO and evinces a new, simple and inexpensive potential therapy for neonatal pulmonary hypertension.
It was found that NO produced by endothelial cells diffuses into smooth muscle cells and interacts with heme as a cofactor of sGS, which is a heterodimeric enzyme with subsequent formation of cGMP. Cyclic GMP activates protein kinase G, which causes phosphorylation of myosin light chain phosphatase, and therefore inactivation of myosin light-chain kinase ultimately leading to the dephosphorylation of the myosin light chain, resulting in smooth muscle relaxation, reduction of pulmonary arterial pressure, and increased oxygenation (Surks, 2007) . NO absorbed from the lungs into the systemic circulation is quickly deactivated by direct interaction with hemoglobin, minimizing its effect on the systemic circulation. Inhaled NO is a selective pulmonary vasodilator that has the ability to produce vasodilation in the pulmonary vascular bed without affecting systemic circulation (Thebaud et al., 1999; Lowson, 2004) . This property of inhaled NO has made it a useful therapy in the management of both adult and pediatric patients with a variety of conditions associated with pulmonary hypertension, with or without hypoxia. Although these studies indicate that NO can significantly reduce blood pressure in models of hypertension, more detailed studies are warranted to determine if NO therapy can lower blood pressure to the same extent as the current standard of care. To overcome this problem, various types of NO donors have been developed over the past 20 years based on understanding the chemical biology and physiology of NO (Thatcher, 2005) . NONOates (diazeniumdiolate NO donors; DEA/NO, PAPA/NO and NOC-5) have been chemically synthesized and extensively studied for preclinical use. In addition, new NO donors are developed for generating NO in a specific organ or tissue. For example, V-PYRRO/NO is a stable NO donor fashioned from a pyrrolidine diazeniumdiolate ion with attached pro-drug groups predicted to be metabolized by cytochrome p-450 and hepatic epoxidase. Intravenous administration of V-PYRRO/ NO selectively replenishes NO in the liver sinusoids in a mouse model of portal hypertension, leading to sinusoidal dilation and therefore, decreased hepatic vascular resistance (Edwards et al., 2008) . This liver-selective drug did not systemically produce NO and subsequently did not affect systemic vascular hemodynamics.
The cytosolic heme-containing sGC is one of the key enzymes in the NO-mediated signaling pathway as well as NO-dependent vascular physiology. The vasodilatory properties of NO have been exploited for over a century in cardiovascular disease, but NO donor drugs and inhaled NO are associated with significant shortcomings, such as resistance to NO in some disease states, the development of tolerance during long-term treatment, non-specific delivery to target sites, and non-specific effects such as post-translational modification of proteins. Thus, development of pharmacological agents capable of directly stimulating the NO receptor, sGC, is highly desirable. The benzylindazole compound YC-1 was the first generation of sGC stimulators to be identified; based on its chemical structure, the second generation of sGC stimulators with improved potency and specificity against sGC has been developed, including CFM-1571 , BAY 41-2272 , BAY 41-8543, and BAY 63-2521 . A sGC stimulator, BAY 63-2521 , is currently in clinical development as an oral therapy for patients with pulmonary hypertension (Stasch and Hobbs, 2009) . A recent study has reported that phase 2 trial of BAY 63-2521 exhibits significant promotion of pulmonary hypertension and pulmonary arterial hypertension (Ghofrani et al., 2010) . These results indicate that NO donors or sGS stimulators, which elevate the intracellular levels of cGMP, can be potentially useful therapeutic agents for patients with hypotension.
Effect of NO on ischemia and reperfusion (I/R) injury
Endogenous or exogenous NO has proven to be therapeutically effective in various models of I/R injury. An animal model of single organ IR injury is generally developed by occlusion of the vascular supply of an organ of interest for a period of time, then releasing the occlusion to permit reperfusion. NO at low concentrations protects cardiomyocytes from I/R injury via sGC activation and subsequent cGMP formation (Kanno et al., 2000; Jones et al., 2004) . NO provides cytoprotective effects in different organs, including liver (Duranski et al., 2005) , heart (Webb et al., 2004; Duranski et al., 2005) , kidney (Tripatara et al., 2007) , and brain (Jung et al., 2006) . Furthermore, several studies have also shown protective effects of NO in vari-ous I/R conditions, including stroke (Jung et al., 2006) , renal ischemia (Tripatara et al., 2007) , and chronic limb ischemia (Kumar et al., 2008) . These effects are associated with a significant increase in blood levels of S-nitrosothiols, which are endogenous transporters of NO used in activator of cGMP-dependent and -independent signaling pathways. All together, the promising animal data discussed here indicate that NO possesses the characteristics of a useful adjunctive therapy for stroke and other conditions of I/R injury.
To date, human clinical trials of NO therapy for organ I/R injury have been conducted with inhaled NO. Although inhaled NO improved oxygenation and decreased pulmonary artery pressure without systemic circulatory effects (Date et al., 1996) , beneficial effects of inhaled NO therapy have been recently reported for liver and lung I/R injuries (Lang et al., 2007; Yerebakan et al., 2009) , demonstrating pharmacological efficacy of NO-based therapy in the setting of I/R injury. However, conventional NO donors have shown pharmacologically significant limitations, including indiscriminate NO release, vehicle toxicity, and triggers of NO generation not practical in an I/R setting model, such as light irradiation (Scatena et al., 2005; Miller and Megson, 2007) . Several types of NO-releasing agents are available. Sodium nitroprusside was first described as a vasodilator in 1929 and is still used to manage hypertensive crisis, as well as try to treat I/R injury in the rat liver (Kuroki et al., 2004) ; however, this compound can exert cytotoxicity because it generates NO in an one step reaction (half life time, 2-26 min) and simultaneously releases the cytotoxic chemical cyanide (CN − ). Exogenous N-bound diazeniumdiolated NO donors, such as 2-(N,N-diethylamino)-diazenolate 2-oxide (DEA/NO) and 2,2'-(hydroxynitrosohydrazono)-bis-ethanimine (DETA/NO), which spontaneously release a bolus of NO into body fluid may be harmful if NO generates the strong oxidant ONOO − by reacting with large concentrations of superoxide anion produced during reperfusion (Schulz et al., 2004) . In contrast, S-nitrosothiols (SNAP and S-nitrosoalbumin), which are useful NO donors for treating I/R injury (Bell et al., 2003) , are the endogenous transporters of NO used in NO-signaling pathways that release NO through direct trans-nitrosation with thiol groups of proteins and non-protein or via decomposition initiated by enzymatic metal centers. Recently, dendritic glutathione-conjugated SNAP (G4-SNAP) has been developed and exhibits NO release characteristics similar to free small molecule nitrosothiols, like SNAP, in solution. However, these dendritic NO release vehicles were more effective at inhibiting platelet aggregation than their small molecule NO donor counterparts. This compound is a strong potential of NO-based therapy for I/R injury in the presence of appropriate concentrations of GSH (Johnson et al., 2010) . Elevation of NO by NOS gene transfer has shown some beneficial effects, such as wound healing, erectile dysfunction, vascular surgery, and transplantation (Schwentker and Billiar, 2002) . Genetic overexpression of eNOS in mice attenuated myocardial infarction after myocardial I/R but fails to significantly protect against post-ischemic myocardial contractile dysfunction in mice (Jones et al., 2004) , indicating that regulation of endogenous NO production attributes protection of organ injury after I/R. Furthermore, cardiomyoctye-specific eNOS overexpression displayed decreased infarct size and preservation of cardiac function compared with systemic transgenic overexpression of eNOS in an in vivo murine model of myocardial I/R injury (Elrod et al., 2006) . These results provide evidence that a site-specific increase in NO production by eNOS gene therapy may be more advantageous in limiting myocardial I/R injury. In addition, NO production by direct intramyocardial injection of adenoviral vector carrying iNOS gene (Ad5/iNOS) in mice increased local iNOS protein expression and activity and markedly reduced infarct size, without perturbation of systemic hemodynamics (Li et al., 2003) . These results indicate that endogenous NO production by delivery of NOS gene or NO donors can mediate the cytoprotective effects that mitigate ischemia/reperfusion injury.
CONCLUSIONS
In summary, NO, generated by constitutive expression or inducible expression of NOS in cells, plays an important role in physiological and pathological conditions, such as the regulation of vascular tone, neurotransmission, and pathogenesis of various diseases. NO elicits opposing mechanisms of action in vascular inflammation, neovascularization, cell survival, tumor growth, and I/R injury in a concentration-dependent manner. Thus, maintenance of appropriate levels of NO is critically important for human health. These evidences indicate that the regulation of endogenous NO levels offers the beneficial opportunity to improve the efficacy of therapeutic applications in human diseases. Several ongoing trials using techniques with NO-generating compounds and NOS gene delivery will provide important insights into the potential benefits of NO therapies, new information about strategic designs for NO donor development, and additional clinical trials aimed at evaluating the therapeutic effects of NO.
